Skip to main content
SpringerLink
Log in

Diclofenac Epolamine (Flector®) Patch

Evidence for Topical Activity

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

This review focuses on previously unpublished clinical and pharmacokinetic data with the diclofenac epolamine (diclofenac hydroxyethylpyrrolidine) patch supporting the hypothesis of a topical effect of this formulation. Previous studies have shown that 1 or 2 weeks of treatment with diclofenac epolamine provides pain relief for various localized musculoskeletal conditions such as ankle sprains, epicondylitis and knee osteoarthritis. The reduction in pain after application of the first patch in 155 patients with painful knee osteoarthritis was significant at the 1-hour time point and was superior to placebo at the 3-hour time point and at all time points thereafter. Comparable results were found in a study of 274 patients with acute ankle sprains, in which pain relief was also significantly superior to placebo at the 3-hour time point. Corresponding single-dose (patch) application for 12 hours in ten healthy volunteers demonstrated that diclofenac first appears in plasma at a mean of 4.5 hours after application (range 2–8 hours). Hence, the patch provided pain relief at a time point at which no diclofenac is assumed to be in plasma, which demonstrates local action in terms of tissue diclofenac accumulation under the patch. This is further supported by an apparent plasma diclofenac half-life of 9–12 hours after patch application, which implies the presence of a tissue reservoir, as the half-life after oral intake of diclofenac is 1–2 hours.

Steady-state plasma diclofenac concentrations are present before 3 days’ application (two patches/day) and are in the order of 1–3 ng/mL. The bioavailability in terms of systemic exposure from the patch compared with oral intake (75 mg/day) is in the order of 1%. Such low diclofenac concentrations are without systemic effects, as demonstrated by the fact that no drug-related gastrointestinal bleeding, ulcers or cutaneous events characteristic of Steven-Johnson syndrome have been reported during 15 years of diclofenac epolamine patch use.

These data provide support for the notion that diclofenac epolamine patch provides pain relief through accumulation of diclofenac under the site of application, without any evidence of systemic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Notes

  1. Trade names: Flector EP Tissugel®, Flector® patch, Dioxaflex®, Flector® EP Pflaster, Dicloplast®, Dicloreum® Tissugel, Votrex® EP Tissugel.

  2. The Osteoarthritis Research Society International (OARSI) is a non-profit scientific professional organization that promotes and encourages fundamental and applied research in osteoarthritis.

References

  1. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for acute pain: a meta-analysis. BMC Family Practice 2004; 17: 5–10

    Google Scholar 

  2. Heynemann CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases. Drugs 2000; 60(3): 555–74

    Article  Google Scholar 

  3. Fini A, Fazio G, Rapaport I. Diclofenac/N-(2-hydroxyethyl)pyrrolidine: a new salt for an old drug. Drugs Exptl Clin Res 1993; 19(3): 81–8

    CAS  Google Scholar 

  4. Brühlmann P, de Vathaire F, Dreiser RL, et al. Short term treatment with topical diclofenac epolamine plaster in patients with symptomatic knee osteoarthritis: pooled analysis of two randomised clinical studies. Curr Med Res Opin 2006; 22(12): 2429–38

    Article  CAS  Google Scholar 

  5. Jousselin E. Flector® Tissugel in the treatment of painful ankle sprains. J Traumatol Sport 2003; 20: 1S5–9

    Google Scholar 

  6. Jenoure P, Rostan A, Gremion G, et al. Multicentre, double-blind controlled clinical study on the efficacy of diclofenac epolamine-Tissugel plaster in patients with epicondylitis. Med Sport (Roma) 1997; 50(3): 285–92

    Google Scholar 

  7. Rovati S. Addendum 2 to clinical trial report (260691): Flector® plaster vs. placebo for treatment of gonarthrosis. Pambio-Noranco, Lugano, Switzerland: IBSA, 2007 31 May. (Data on file)

  8. Brewer A, Lanzarotti A, Yanchik J, et al. Evaluation of treatment of mild to moderate acute pain of ankle sprain with diclofenac epolamine topical patch. American Academy of Nurse Practitioners; 2008 Jun 28-Jul 1; Washington, DC

  9. Study report CRO-PK-02-76. Epicutaneous absorption of diclofenac epolamine after single dose and at steady state after administration of Flector EP Tissugel® to 10 male and female healthy volunteers. Pambio-Noranco, Lugano, Switzerland: IBSA, 2002 Nov 14. (Data on file)

  10. Assandri A, Canali S, Giachetti C. Local tolerability and pharmacokinetic profile of a new transdermal delivery system, diclofenac hydroxyethylpyrrolidine plaster. Drug Exptl Clin 1993; 19(3): 89–95

    CAS  Google Scholar 

  11. Moore N. Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin Drug Invest 2007; 27(3): 163–95

    Article  CAS  Google Scholar 

  12. Study report CRO-PK-00-33. Influence of exercise on the absorption of diclofenac epolamine (DHEP) in healthy male volunteers administered epicutaneously Flector EP-Tissugel®. Pambio-Noranco, Lugano, Switzerland: IBSA, 2000 Nov 19. (Data on file)

  13. Study report CRO-PK-98-13. Bioavailability study of a new topical formulation of the diclofenac epolamine plaster containing heparin vs the marketed formulation Flector EP-Tissugel® in male and female healthy volunteers. Pambio-Noranco, Lugano, Switzerland: IBSA, 1999 May 25. (Data on file)

    Google Scholar 

  14. Shah AK, Wei G, Lanman RC, et al. Percutaneous absorption of ketoprofen from different anatomical sites in man. Pharm Res 1996; 13(1): 168–72

    Article  CAS  Google Scholar 

  15. Rusca A, Mautone G, Sun S, et al. Comparison of plasma pharmacokinetics of Flector® patch (diclofenac epolamine topical patch) 1.3% and oral Voltaren® (diclofenac sodium enteric-coated tablets) in healthy volunteers [abstract no. 68]. J Pain 2008; 9(4 Suppl. 1): 45

    Article  Google Scholar 

  16. Hinz B, Chevts J, Renneret B, et al. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006; 54(1): 282–91

    Article  CAS  Google Scholar 

  17. Warner TD, Guiliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563–8

    Article  CAS  Google Scholar 

  18. Musterhjelm E, Niemi TT, Ylikorkola O, et al. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro. Acta Anaesthesiol Scand 2005; 49: 840–6

    Article  CAS  Google Scholar 

  19. Data on file, IBSA. Flector patch, clinical overview, 2007 Sept 30

  20. Data on file, IBSA. Diclofenac epolamine plaster. CIOMS II/ Periodic Safety Update Report 1993-2007

  21. Brunner M, Dehghanyar P, Scigfried B, et al. Favourable dermal penetration of diclofenac after administration to the skin using a novel sprays gel formulation. Br J Clin Pharm 2005; 60(5): 573–7

    Article  CAS  Google Scholar 

  22. Rolf C, Engstroem B, Beauchard C, et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology 1999; 38: 564–7

    Article  CAS  Google Scholar 

  23. Domenikus M, Nicolarkis M, Krotz R, et al. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung/Drug Res 1996; 46(II): 1138–43

    Google Scholar 

  24. Gallacchi G, Marcolongo R. Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion. Drug Exptl Clin Res 1993; 19(3): 95–7

    CAS  Google Scholar 

  25. Burian M, Tegeder I, Seegel M, et al. Peripheral and central hyperalgesic effects of diclofenac in a model of human inflammatory pain. Clin Pharmacol Ther 2003; 74: 113–20

    Article  CAS  Google Scholar 

  26. Brandt K. Paracetamol in the treatment of osteoarthritis pain. Drugs 2003; 63(2): 23–41

    Article  CAS  Google Scholar 

  27. Dehghanyar P, Mayer BX, Namiranian K, et al. Topical skin penetration of diclofenac after single- and multiple-dose application. Int J Clin Pharmacol Ther 2004; 42(7): 353–9

    Article  CAS  Google Scholar 

  28. Sioufi A, Pommier F, Boschet F, et al. Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel. Biopharm Drug Disp 1994; 15: 441–9

    Article  CAS  Google Scholar 

  29. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet 1997; 33(3): 184–213

    Article  CAS  Google Scholar 

  30. Dreiser RL, Marty M, Ionesca E, et al. Relief of acute low back pain with diclofenac-K 12.5mg tablets: a flexible dose, ibuprofen 200mg and placebo-controlled trial. Int J Clin Pharmacol Ther 2003; 41(9): 375–85

    Article  CAS  Google Scholar 

  31. Moskowitz RW, Sunshine A, Hooper M, et al. An analgesic model for assessment of acute pain response in osteoarthritis of the knee. Osteoarthritis Cartil 2006; 14: 1111–8

    Article  CAS  Google Scholar 

  32. Hewitt DJ, Knox HT, Xiam J, et al. Tramadol/acetaminophen or hydrocodone/acetaminophen for the treatment of ankle sprain: a randomized, placebo-controlled study. Ann Emerg Med 2007; 49: 468–80

    Article  Google Scholar 

  33. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part II. OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartil 2008; 16: 137–62

    Article  CAS  Google Scholar 

  34. Evans JMM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995; 311: 22–6

    Article  CAS  Google Scholar 

Download references

Acknowledgements

IBSA (Institut Biochimique SA) sponsored the studies described in this review. Dr Rovati is an employee of IBSA. Dr Petersen has no conflicts of interest that are directly relevant to the content of this review. The authors would like to thank Wolters Kluwer Health for editorial assistance.

Author information

Authors and Affiliations

  1. Copenhagen, Denmark

    Birte Petersen (Consulting Physician)

  2. Research & Development Department, IBSA Institut Biochimique SA, Via del Piano, 6915, Pambio-Noranco, Lugano, Switzerland

    Stefano Rovati

Authors
  1. Birte Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Rovati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Birte Petersen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petersen, B., Rovati, S. Diclofenac Epolamine (Flector®) Patch. Clin. Drug Investig. 29, 1–9 (2009). https://doi.org/10.2165/0044011-200929010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0044011-200929010-00001

Keywords

Search

Navigation